orelabrutinib
innocare,biogen
['orelabrutinib']
the combination of orelabrutinib plus the r-chop regimen revealed a positive overall response rate of 86.4% when given to patients with non-germinal center b cell-like diffuse large b-cell lymphoma. #lymsm #esmo2022 #dlbcl 
Oncology news and insights from leading researchers and cancer centers.